Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309074 | 0.85 | CYP1A2 (0.40) | CYP1A2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL26969122 | 0.83 | HDAC6 (0.43) | CYP1A2KMT2AMAPTALDH1A1GAA | |
| SCHEMBL27137687 | 0.80 | KMT2A (0.36) | CYP1A2KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL2929174 | 0.79 | NPC1 (0.41) | CYP1A2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL23535249 | 0.79 | KMT2A (0.41) | CYP1A2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL31389811 | 0.79 | MAPT (0.37) | CYP1A2KMT2AMAPTLMNATP53 | |
| SCHEMBL2522852 | 0.78 | PDCD1 (0.43) | CYP1A2KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL24812522 | 0.78 | RAB9A (0.37) | CYP1A2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL2928372 | 0.78 | NPC1 (0.43) | CYP1A2KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL38663129 | 0.78 | TP53 (0.41) | KMT2AKDM4EMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | CYP1A2 234/4885KMT2A 531/4885KDM4E 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.